IP Library Granted Patent US 10,137,166
Granted Patent B2
US 10,137,166 · App. 15/341,949 · Granted Nov 27, 2018

Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions

Inventors: Rutledge Ellis-Behnke (Canton, MA); Yu-Xiang Liang (Hong Kong, CN); Gerald E. Schneider (Somerville, MA); Kwok-Fai So (Hong Kong, CN); David K. C. Tay (Hong Kong, CN)
Assignees: Massachusetts Institute of Technology; Versitech Limited
A61K38/10A61K31/167A61L15/42A61L26/0061
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,137,166
App. No.
15/341,949
Granted
Nov 27, 2018
Kind
B2
Abstract

Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid. The formulation may be administered to a burn or ulcer. In one embodiment, the formulation is provided as a dry or lyophilized powder. In another embodiment, the material is provided in water. In another embodiment, the material is provided in combination with an oil and forms a laminate.

Claims (24)

1. A composition for making an in vivo barrier structure, comprising self-assembling peptidomimetics, comprising between 6-64 alternating hydrophobic and hydrophilic residues,

wherein the hydrophilic residues alternate between positively-charged and negatively-charged residues,

wherein the self-assembling peptidomimetics are copolymers of two or more selected from the group consisting of α-peptides, β-peptides,γ-peptides, and δ-peptides,

wherein the self-assembling peptidomimetics are able, upon interaction with at least one ionic species present at a site of a wound or injury or surgery on or in a subject, to form a structure that inhibits movement of a bodily fluid and/or contaminant of the subject.

2. The composition as in claim 1 , wherein the composition is in solid form.

3. The composition as in claim 1 , wherein the composition is a liquid.

4. The composition as in claim 2 , wherein the solid is in a form selected from the group consisting of a dry powder, a tablet, and a coating on a medical device.

5. The composition as in claim 1 , wherein the composition is dispersed on or within, absorbed on or within, or applied to a nasal plug, bandage, suture, tape, adhesive, surgical drape, foam, or matrix.

6. The composition as in claim 1 , wherein the composition is capable of being dispensed as a spray.

7. The composition as in claim 3 , wherein the self-assembling peptidomimetics are in an aqueous solution at a concentration of between 0.1% weight to volume and 10% weight to volume, inclusive.

8. The composition as in claim 7 , wherein the solution comprises a concentration of Li+, Na+, K+, and Cs+ions between 0.1 mM and 50 mM.

9. A kit, comprising

(i) the composition of claim 1 , and

(ii) instructions for use of the composition in inhibiting movement of a bodily fluid and/or contaminant.

10. The kit of claim 9 , wherein the kit further comprises a syringe or vessel comprising one or more compartments,

wherein a first compartment comprises the composition and a second compartment comprises a solution which, when combined with the composition, dissolves or hydrates the composition.

11. The composition of claim 1 , further comprising an agent selected from the group consisting of therapeutic agent, prophylactic agent, diagnostic agent, a pharmaceutically acceptable diluent, and a pharmaceutically filler.

12. The composition of claim 11 , wherein the therapeutic agent is selected from the group consisting of anti-inflammatories, vasoconstrictors, anti-infectives, anesthetics, biomolecules, antibiotics, and vitamins.

13. The composition of claim 1 , further comprising a growth factor.

14. The composition of claim 1 , wherein the co-polymer of self-assembling peptidomimetics comprises between 8 and 32 residues.

15. The composition of claim 1 , wherein the co-polymer of self-assembling peptidomimetics comprises the amino acid sequence RADARADARADARADA (SEQ ID NO: 1).

16. A self-assembled barrier structure comprising peptidomimetics,

wherein the structure is formed from the self-assembly of the composition of claim 1 , and

wherein the structure prevents the passage of bodily fluids through the structure.

Assignments (4)
CONFIRMATORY LICENSE Recorded Nov 4, 2022
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061882/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2017
From: ELLIS-BEHNKE, RUTLEDGE; SCHNEIDER, GERALD E.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 041110/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2017
From: LIANG, YU-XIANG; SO, KWOK-FAI; TAY, DAVID
To: THE UNIVERSITY OF HONG KONG
Reel/Frame 041110/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2017
From: THE UNIVERSITY OF HONG KONG
To: VERSITECH LIMITED
Reel/Frame 041110/0255 →
Continuity (4)
Continuation 14748185 · Jun 23, 2015
Division 11796132 · Apr 25, 2007
Provisional Application 60745601 · Apr 25, 2006
Related Publication 20170143788A1 · May 25, 2017